FDX1 and nonpapillary renal cell carcinoma: We thus hypothesized that the use of elesclomol might be the proper approach for ccRCC therapy based on cuproptosis restoration, instead of the over-expression of FDX1, which might cause off-target effects of in situ overexpression.